TrialThe oncologist2021

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.

Vicky Makker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.